Lebrikizumab for severe itching and bumps in prurigo nodularis
Treatments studied
Part of Skin clinical trials.
This study tests whether a drug called lebrikizumab can reduce severe itching and skin bumps caused by prurigo nodularis (a chronic skin condition). The drug works by calming an overactive immune response in the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–80 years old
- You've had prurigo nodularis for at least 1 year with moderate-to-severe itching and bumps in multiple body areas
- You cannot be pregnant, breastfeeding, or planning to become pregnant during the study; women and men must use effective contraception for at least 18 weeks after treatment ends
- You cannot have had cancer in the past 5 years (except early cervical cancer or non-melanoma skin cancers that were successfully treated)
- You cannot have HIV, active hepatitis, liver cirrhosis, severe uncontrolled asthma, or a weakened immune system
- You must stop using other PN treatments (creams, pills, light therapy) and immune-suppressing drugs during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ICP-332 for people with prurigo nodularis (a condition causing very itchy, hard bumps on the skin). It aims to see if the drug can safely reduce itching and improve skin lesions.
This study follows people with moderate-to-severe prurigo nodularis who are starting dupilumab. It looks at how the medicine works over time and how it affects the immune system, to help understand long-term benefits.
This study tests whether lebrikizumab, a new injection, can reduce nummular eczema (coin-shaped eczema patches) in adults whose condition hasn't improved with topical steroid creams. It's designed to help people with moderate-to-severe nummular eczema who need a stronger treatment option.
This study looks at how well nemolizumab works in real-world settings for adults with moderate-to-severe prurigo nodularis, a skin condition that causes intense itching and bumps. If you are starting this medication as part of your normal care, you may be able to join.
This trial tests an injectable drug called lebrikizumab for people with moderate-to-severe eczema (atopic dermatitis) that has not been well controlled with topical treatments. It may help reduce skin symptoms and itching.
This trial tests an injection called SHR-1819 for adults with prurigo nodularis, a skin condition with itchy bumps. The goal is to see if it helps reduce itching and bumps.
Hear when a new Prurigo Nodularis (PN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.